Profile
Wilfried van Langenaeker was the founder and had founded Silicos SA in 2005, where he held the title of Chief Executive Officer from 2005 to 2012.
He also worked as a Principal at The University of North Carolina at Charlotte.
Dr. van Langenaeker received his undergraduate degree in 1989 and his doctorate in 1994 from Université Libre de Bruxelles.
Former positions of Wilfried van Langenaeker
| Companies | Position | End |
|---|---|---|
Silicos SA
 Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Founder | 2012-05-10 |
| The University of North Carolina at Charlotte | Corporate Officer/Principal | - |
Training of Wilfried van Langenaeker
| Université Libre de Bruxelles | Undergraduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Health Technology |
- Stock Market
- Insiders
- Wilfried van Langenaeker
